Literature DB >> 35394596

A review on structural genomics approach applied for drug discovery against three vector-borne viral diseases: Dengue, Chikungunya and Zika.

Shobana Sundar1, Shanmughavel Piramanayagam1, Jeyakumar Natarajan2.   

Abstract

Structural genomics involves the advent of three-dimensional structures of the genome encoded proteins through various techniques available. Numerous structural genomics research groups have been developed across the globe and they contribute enormously to the identification of three-dimensional structures of various proteins. In this review, we have discussed the applications of the structural genomics approach towards the discovery of potential lead-like molecules against the genomic drug targets of three vector-borne diseases, namely, Dengue, Chikungunya and Zika. Currently, all these three diseases are associated with the most important global public health problems and significant economic burden in tropical countries. Structural genomics has accelerated the identification of novel drug targets and inhibitors for the treatment of these diseases. We start with the current development status of the drug targets and antiviral drugs against these three diseases and conclude by describing challenges that need to be addressed to overcome the shortcomings in the process of drug discovery.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chikungunya; Dengue; Structural genomics; Vector-borne viral diseases; Zika

Mesh:

Year:  2022        PMID: 35394596     DOI: 10.1007/s11262-022-01898-5

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  168 in total

1.  Global efforts in structural genomics.

Authors:  R C Stevens; S Yokoyama; I A Wilson
Journal:  Science       Date:  2001-10-05       Impact factor: 47.728

Review 2.  Dengue: a continuing global threat.

Authors:  Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling
Journal:  Nat Rev Microbiol       Date:  2010-12       Impact factor: 60.633

Review 3.  Structural genomics of GPCRs.

Authors:  Kenneth Lundstrom
Journal:  Trends Biotechnol       Date:  2005-02       Impact factor: 19.536

Review 4.  Structural genomics for membrane proteins.

Authors:  K Lundstrom
Journal:  Cell Mol Life Sci       Date:  2006-11       Impact factor: 9.261

Review 5.  Structural genomics and drug discovery: all in the family.

Authors:  Johan Weigelt; Linda D B McBroom-Cerajewski; Matthieu Schapira; Yong Zhao; Cheryl H Arrowsmith; Cheryl H Arrowmsmith
Journal:  Curr Opin Chem Biol       Date:  2008-03-07       Impact factor: 8.822

Review 6.  Doing more than just the structure-structural genomics in kinase drug discovery.

Authors:  Brian D Marsden; Stefan Knapp
Journal:  Curr Opin Chem Biol       Date:  2008-02-29       Impact factor: 8.822

7.  The flavivirus precursor membrane-envelope protein complex: structure and maturation.

Authors:  Long Li; Shee-Mei Lok; I-Mei Yu; Ying Zhang; Richard J Kuhn; Jue Chen; Michael G Rossmann
Journal:  Science       Date:  2008-03-28       Impact factor: 47.728

8.  A cocrystal structure of dengue capsid protein in complex of inhibitor.

Authors:  Hongjie Xia; Xuping Xie; Jing Zou; Christian G Noble; William K Russell; Luis Marcelo F Holthauzen; Kyung H Choi; Mark A White; Pei-Yong Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

9.  A ligand-binding pocket in the dengue virus envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-20       Impact factor: 11.205

Review 10.  The Challenges Imposed by Dengue, Zika, and Chikungunya to Brazil.

Authors:  Paolo Marinho de Andrade Zanotto; Luciana Cezar de Cerqueira Leite
Journal:  Front Immunol       Date:  2018-08-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.